Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study-Reference-Cited by-同舟云学术

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study

Published:2021-11 Issue:11 Volume:6 Page:889-902
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Cusi Kenneth,Alkhouri Naim,Harrison Stephen A,Fouqueray Pascale,Moller David E,Hallakou-Bozec Sophie,Bolze Sebastien,Grouin Jean-Marie,Jeannin Megnien Sophie,Dubourg Julie,Ratziu Vlad

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies;Stefan;Lancet Diabetes Endocrinol,2019

3. Current efforts and trends in the treatment of NASH;Ratziu;J Hepatol,2015

4. The race to bash NASH: emerging targets and drug development in a complex liver disease;Romero;J Med Chem,2020

5. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options;Gastaldelli;JHEP Rep,2019

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. The pro-drug C13 activates AMPK by two distinct mechanisms;Biochemical Journal;2024-09-12

3. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-10

4. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies;Chinese Journal of Natural Medicines;2024-08

5. Chlormequat chloride induces hepatic steatosis by promoting mTOR/SREBP1 mediated lipogenesis via AMPK inhibition;Food and Chemical Toxicology;2024-08